NCT04880785
Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine
레지스트리 요약
- 진행 상태
- 완료 (COMPLETED)
- 질환/조건
- HIV Infections
- 시험 유형
- 중재 연구 (INTERVENTIONAL)
- 단계
- Phase 2
- 목적
- 치료
- 중재 유형
- 약물
- 개입·치료
- Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]
- Lead Sponsor
- Fundacion SEIMC-GESIDA (기타)
캐시 시각: 2026-09-10 09:08:12
요약
Dolutegravir (DTG) plus lamivudine (3TC) is a dual regimen combination recommended for both naïve and suppressed persons with HIV-1 infection1. However, data regarding the efficacy of this regimen in suppressed persons with history of past resistance or virologic failures is currently insufficient. This is a phase IIa, open-label, single arm, multicentric study.
The hypothesis is that therapy with DTG/3TC would be able to maintain viral control in HIV infected participants with prior history of 3TC resistance but without evidence of M184V/I resistance mutation in proviral DNA population sequencing at baseline. The investigators also hypothesize that archived minority 3TC resistance associated mutations detected by next-generation (NGS) sequencing prior to the switch would not have a significant impact on the efficacy of DTG/3TC.
The hypothesis is that therapy with DTG/3TC would be able to maintain viral control in HIV infected participants with prior history of 3TC resistance but without evidence of M184V/I resistance mutation in proviral DNA population sequencing at baseline. The investigators also hypothesize that archived minority 3TC resistance associated mutations detected by next-generation (NGS) sequencing prior to the switch would not have a significant impact on the efficacy of DTG/3TC.
카카오 로그인 후 의뢰